The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 21, 2022

Filed:

Oct. 20, 2017
Applicants:

Inserm (Institut National DE LA Santé ET DE LA Recherche Médicale), Paris, FR;

Université DE Nantes, Nantes, FR;

Ose Immunotherapeutics, Nantes, FR;

Inventors:

Elise Chiffoleau, Nantes, FR;

Géraldine Teppaz, St. Herblain, FR;

Nicolas Poirier, Treillieres, FR;

Bernard Vanhove, Rezé, FR;

Vanessa Gauttier, Rezé, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61P 35/00 (2006.01); C07K 14/47 (2006.01); C12N 15/115 (2010.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2851 (2013.01); A61P 35/00 (2018.01); C07K 14/4726 (2013.01); C12N 15/115 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2319/30 (2013.01);
Abstract

The present invention relates to methods for promoting T cells response. The inventors examined the expression and function of CLEC-1 in human DCs and demonstrated for the first time a cell-surface expression. They investigated its functional role following triggering on orchestration of T-cell responses. The inventors showed in vitro and in vivo with CLEC-1 deficient rats and rat CLEC-1 Fc fusion protein that disruption of CLEC-1 signalling enhances in vitro Th17 activation and in vivo enhances T cell priming and Th17 and Th1 activation. In particular, the present invention relates to CLEC-1 antagonists for promoting T cells response in a subject in need thereof.


Find Patent Forward Citations

Loading…